Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Fujirebio Inc. has 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are assigned to 2 distinct examiners and are located in 2 distinct art units. This spread shows that the company's current filings are being evaluated by different technical groups, which may require different specialized arguments to overcome examiner rejections.
MARVICH, MARIA is the busiest examiner for the portfolio, managing 1 pending office action. Given the total of 2 pending office actions, the workload is shared equally between the 2 distinct examiners. The presence of 2 distinct art units indicates that the applications involve different specialized areas of biotechnology or pharmaceuticals. This decentralized approach means that the company's success is not dependent on the decision of a single examiner or art unit.
For the applicant, managing 2 pending office actions requires addressing the specific requirements of two different examiners. The involvement of 2 distinct art units means there is no central technical review for these matters. With 1 pending office action assigned to the busiest examiner, the company must maintain two separate prosecution tracks. Effectively resolving the 2 pending office actions involves navigating the unique procedural and technical hurdles present in each of the 2 distinct art units.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MARVICH, MARIA | 1 | 54.9% | +28.1% |
| EVANS, CHRISTOPHER RYAN | 1 | 60.9% | +64.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18553439 | METHOD FOR TREATING BIOLOGICAL SAMPLE | MARVICH, MARIA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17913363 | METHOD FOR MEASURING FRAGMENTS CONTAINING HUMAN TYPE IV COLLAGEN 7S DOMAIN AND KIT FOR USE THEREIN | EVANS, CHRISTOPHER RYAN | 119d overdue |
| 18553439 | METHOD FOR TREATING BIOLOGICAL SAMPLE | MARVICH, MARIA | — |
| Art Unit | Apps |
|---|---|
| 1634 | 1 |
| 1677 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18553439 | METHOD FOR TREATING BIOLOGICAL SAMPLE | MARVICH, MARIA | 1634 | §103§112 | Final Rejection | — | Pending | Sep 29, 2023 |
| 17913363 | METHOD FOR MEASURING FRAGMENTS CONTAINING HUMAN TYPE IV COLLAGEN 7S DOMAIN AND KIT FOR USE THEREIN | EVANS, CHRISTOPHER RYAN | 1677 | §103 | Non-Final OA | 119d overdue | Pending | Sep 21, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial